Yet apparently insurance companies are still testing for cotinine, which shows up in anyone who uses nicotine in any form -- thus punishing the quitters as much as the smokers. And it's total BS that smokers cost more, since they often die much younger than those who quit, so it's entirely punitive.
Andria
And from the workshop thread in Regulation.. not sure if you followed that one Andria....
My post:
Their (@1:30-2:00pm) discussion of dual uses poses huge problems with biomarkers - how to differentiate those from cigarette smoking vs vaping. One comment by Hecht, in general regarding the numerous types of ecigs available now and dual use:
"I mean clearly as I try to design our program, we've always known that scientific challenges involved here way too big for us to tackle."
The problem with identifying biomarkers for vaping is dual use. How can one say the cotinine is from a cigarette or ecig? Plus the trace amounts of 'toxins' in ecigs are really hard to tag and read. ANTZ can say there are toxins but